Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigens, Neoplasm | 5 | 2022 | 1505 | 1.290 |
Why?
|
| Carcinogenesis | 5 | 2021 | 1030 | 1.220 |
Why?
|
| Cancer Vaccines | 3 | 2022 | 697 | 1.210 |
Why?
|
| Ubiquitination | 3 | 2023 | 578 | 0.970 |
Why?
|
| Tumor Escape | 2 | 2023 | 251 | 0.930 |
Why?
|
| Herpesvirus 4, Human | 3 | 2023 | 968 | 0.920 |
Why?
|
| RNA, Long Noncoding | 8 | 2021 | 601 | 0.910 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2021 | 156 | 0.890 |
Why?
|
| Lymphoma | 2 | 2022 | 1466 | 0.880 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2021 | 3552 | 0.780 |
Why?
|
| TNF Receptor-Associated Factor 4 | 1 | 2020 | 23 | 0.730 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 8 | 2022 | 1666 | 0.720 |
Why?
|
| Herbicides | 1 | 2019 | 14 | 0.700 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 151 | 0.690 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 2150 | 0.690 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2020 | 174 | 0.680 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 32 | 0.680 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 1023 | 0.680 |
Why?
|
| Glycine | 1 | 2019 | 289 | 0.590 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2022 | 811 | 0.560 |
Why?
|
| Neoplasms | 13 | 2022 | 15201 | 0.560 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2019 | 494 | 0.560 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 894 | 0.520 |
Why?
|
| NF-kappa B | 1 | 2021 | 1551 | 0.470 |
Why?
|
| Immunotherapy | 7 | 2022 | 3346 | 0.410 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 15706 | 0.340 |
Why?
|
| Sarcoma | 1 | 2019 | 1726 | 0.340 |
Why?
|
| MicroRNAs | 7 | 2021 | 2956 | 0.340 |
Why?
|
| Glioma | 1 | 2019 | 1971 | 0.320 |
Why?
|
| Cytoskeletal Proteins | 2 | 2020 | 493 | 0.320 |
Why?
|
| Animals | 16 | 2023 | 59506 | 0.310 |
Why?
|
| Mutation | 5 | 2023 | 15185 | 0.310 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 650 | 0.300 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 471 | 0.300 |
Why?
|
| Cell Line, Tumor | 9 | 2023 | 14588 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 8891 | 0.260 |
Why?
|
| Mice | 8 | 2023 | 34407 | 0.250 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2023 | 1051 | 0.250 |
Why?
|
| Humans | 39 | 2023 | 262184 | 0.250 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 3583 | 0.250 |
Why?
|
| Biomarkers, Tumor | 8 | 2021 | 10355 | 0.240 |
Why?
|
| Prognosis | 12 | 2022 | 21745 | 0.240 |
Why?
|
| Nasopharyngeal Neoplasms | 3 | 2020 | 325 | 0.230 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 2868 | 0.230 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 4868 | 0.210 |
Why?
|
| Immune Evasion | 1 | 2023 | 74 | 0.210 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2022 | 30 | 0.210 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2022 | 140 | 0.210 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2021 | 36 | 0.200 |
Why?
|
| RNA, Antisense | 1 | 2021 | 68 | 0.200 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2021 | 26 | 0.200 |
Why?
|
| Tumor Hypoxia | 1 | 2021 | 24 | 0.190 |
Why?
|
| Cell Movement | 4 | 2021 | 2464 | 0.190 |
Why?
|
| Molecular Mimicry | 1 | 2021 | 72 | 0.190 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2023 | 305 | 0.190 |
Why?
|
| Stathmin | 1 | 2020 | 30 | 0.190 |
Why?
|
| Down-Regulation | 3 | 2020 | 2078 | 0.180 |
Why?
|
| Liposomes | 1 | 2022 | 682 | 0.180 |
Why?
|
| GTPase-Activating Proteins | 1 | 2020 | 127 | 0.180 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2019 | 47 | 0.180 |
Why?
|
| HEK293 Cells | 2 | 2021 | 1502 | 0.170 |
Why?
|
| Karyopherins | 1 | 2020 | 136 | 0.170 |
Why?
|
| Antigen Presentation | 1 | 2020 | 272 | 0.170 |
Why?
|
| Cell Membrane | 1 | 2023 | 855 | 0.170 |
Why?
|
| Cytoskeleton | 1 | 2020 | 268 | 0.170 |
Why?
|
| Water Pollutants, Chemical | 1 | 2019 | 37 | 0.170 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 270 | 0.170 |
Why?
|
| Adenosine | 1 | 2021 | 291 | 0.170 |
Why?
|
| Chromosomes, Human, X | 1 | 2020 | 191 | 0.170 |
Why?
|
| Splenomegaly | 1 | 2019 | 158 | 0.170 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2020 | 491 | 0.170 |
Why?
|
| Hydrazines | 1 | 2020 | 208 | 0.170 |
Why?
|
| RNA-Binding Proteins | 2 | 2021 | 984 | 0.160 |
Why?
|
| Mammary Glands, Human | 1 | 2019 | 184 | 0.160 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2019 | 158 | 0.160 |
Why?
|
| Fibroblast Growth Factors | 1 | 2020 | 261 | 0.160 |
Why?
|
| Proteolysis | 1 | 2020 | 368 | 0.160 |
Why?
|
| Cellular Reprogramming | 1 | 2020 | 194 | 0.160 |
Why?
|
| Microfilament Proteins | 1 | 2021 | 488 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2022 | 556 | 0.150 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2021 | 273 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 573 | 0.150 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 5122 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2022 | 3830 | 0.140 |
Why?
|
| Enzyme Activation | 1 | 2020 | 1763 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 587 | 0.140 |
Why?
|
| Triazoles | 1 | 2020 | 619 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 390 | 0.140 |
Why?
|
| Peptides | 1 | 2022 | 1477 | 0.140 |
Why?
|
| Transcriptome | 2 | 2022 | 1859 | 0.140 |
Why?
|
| Cell Proliferation | 4 | 2021 | 7241 | 0.130 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 11575 | 0.130 |
Why?
|
| Disease Progression | 3 | 2021 | 6696 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2020 | 994 | 0.120 |
Why?
|
| Peptide Fragments | 1 | 2020 | 1265 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 1547 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 14300 | 0.120 |
Why?
|
| Female | 13 | 2023 | 142232 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1251 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2333 | 0.110 |
Why?
|
| DNA Damage | 1 | 2020 | 1955 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2020 | 4813 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 5154 | 0.100 |
Why?
|
| Rituximab | 3 | 2022 | 1535 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 2266 | 0.100 |
Why?
|
| Stomach Neoplasms | 2 | 2020 | 2282 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2021 | 973 | 0.090 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 2 | 2021 | 159 | 0.090 |
Why?
|
| 3' Untranslated Regions | 2 | 2020 | 345 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 3318 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2020 | 4317 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 3987 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 6912 | 0.080 |
Why?
|
| Prednisone | 2 | 2022 | 983 | 0.080 |
Why?
|
| RNA, Viral | 2 | 2020 | 666 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 4382 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 5436 | 0.070 |
Why?
|
| Vincristine | 2 | 2022 | 1511 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2020 | 5257 | 0.070 |
Why?
|
| Brain | 1 | 2019 | 4111 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5187 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5540 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 2323 | 0.070 |
Why?
|
| Dexamethasone | 2 | 2021 | 1450 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 3977 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2022 | 1494 | 0.060 |
Why?
|
| Adult | 5 | 2022 | 78082 | 0.060 |
Why?
|
| Male | 8 | 2023 | 123269 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2021 | 2448 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 15874 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2022 | 3002 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2022 | 3005 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5339 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2020 | 32986 | 0.050 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2021 | 42 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2288 | 0.050 |
Why?
|
| Silicon Dioxide | 1 | 2021 | 50 | 0.050 |
Why?
|
| Phosphatidylinositols | 1 | 2021 | 60 | 0.050 |
Why?
|
| A549 Cells | 1 | 2021 | 124 | 0.050 |
Why?
|
| Polymerization | 1 | 2020 | 17 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 241 | 0.050 |
Why?
|
| X Chromosome Inactivation | 1 | 2020 | 74 | 0.040 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 27 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 347 | 0.040 |
Why?
|
| Germinal Center | 1 | 2020 | 161 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 320 | 0.040 |
Why?
|
| Breast Diseases | 1 | 2021 | 201 | 0.040 |
Why?
|
| Heterografts | 1 | 2021 | 734 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 871 | 0.040 |
Why?
|
| Adenine | 1 | 2021 | 638 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 1180 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 1489 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 8883 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2020 | 731 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2020 | 416 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 1027 | 0.040 |
Why?
|
| Cadherins | 1 | 2020 | 663 | 0.040 |
Why?
|
| Methotrexate | 1 | 2020 | 1012 | 0.040 |
Why?
|
| beta Catenin | 1 | 2020 | 687 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2020 | 1112 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 583 | 0.030 |
Why?
|
| Apoptosis | 2 | 2020 | 7608 | 0.030 |
Why?
|
| Transfection | 1 | 2021 | 2934 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2023 | 1958 | 0.030 |
Why?
|
| Piperidines | 1 | 2021 | 1051 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 2020 | 714 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2020 | 1382 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 2281 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2020 | 685 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2021 | 3190 | 0.030 |
Why?
|
| Autophagy | 1 | 2021 | 929 | 0.030 |
Why?
|
| Proteomics | 1 | 2022 | 1382 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1298 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1047 | 0.030 |
Why?
|
| Cytarabine | 1 | 2020 | 1973 | 0.030 |
Why?
|
| Smoking | 1 | 2023 | 2444 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2021 | 807 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 3442 | 0.030 |
Why?
|
| Middle Aged | 4 | 2021 | 86445 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 2478 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 5387 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2021 | 11970 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1587 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 1448 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 5083 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 1828 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 6105 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 6038 | 0.020 |
Why?
|
| Aged | 3 | 2021 | 70323 | 0.020 |
Why?
|
| Models, Biological | 1 | 2019 | 3249 | 0.020 |
Why?
|
| Algorithms | 1 | 2022 | 3891 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2023 | 9294 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 2745 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 1867 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 9186 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 13672 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 14902 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 21473 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 29997 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 31247 | 0.010 |
Why?
|
| Child | 1 | 2020 | 29125 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 38006 | 0.010 |
Why?
|